PRIMAXIN 500 POWDER FOR SOLUTION

Valsts: Kanāda

Valoda: angļu

Klimata pārmaiņas: Health Canada

Aktīvā sastāvdaļa:

IMIPENEM; CILASTATIN (CILASTATIN SODIUM)

Pieejams no:

MERCK CANADA INC

ATĶ kods:

J01DH51

SNN (starptautisko nepatentēto nosaukumu):

IMIPENEM AND CILASTATIN

Deva:

500MG; 500MG

Zāļu forma:

POWDER FOR SOLUTION

Kompozīcija:

IMIPENEM 500MG; CILASTATIN (CILASTATIN SODIUM) 500MG

Ievadīšanas:

INTRAVENOUS

Vienības iepakojumā:

25 VIALS (100 OR 250 ML)

Receptes veids:

Prescription

Ārstniecības joma:

CARBAPENEMS

Produktu pārskats:

Active ingredient group (AIG) number: 0218820001; AHFS:

Autorizācija statuss:

MARKETED

Autorizācija datums:

2006-12-13

Produkta apraksts

_ _
_PRIMAXIN_
_®_
_ (imipenem and cilastatin sodium for injection, USP) _
_Page 1 of 61 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PRIMAXIN®
imipenem and cilastatin for injection, USP
500 mg imipenem and 500 mg cilastatin (as cilastatin sodium) per vial
Sterile powder for solution, I.V. Infusion
ANTIBIOTIC
Merck Canada Inc.
16750 route Transcanadienne
Kirkland QC Canada H9H 4M7
www.merck.ca
Date of Initial Authorization:
JUL 07,1987
Date of Revision:
DEC 21, 2021
Submission Control Number: 253551
_ _
_PRIMAXIN_
_®_
_ (imipenem and cilastatin sodium for injection, USP) _
_Page 2 of 61 _
RECENT MAJOR LABEL CHANGES
4. DOSAGE AND ADMINISTRATION, 4.1 Dosing Considerations
12/2021
4. DOSAGE AND ADMINISTRATION
06/2020
7. WARNINGS AND PRECAUTIONS
06/2020
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED
.
[To update, right-click anywhere in the Table of Contents and select
“Update Field”, “Update entire
table”, click OK.]
RECENT MAJOR LABEL CHANGES
...........................................................................................
2
TABLE OF CONTENTS
.............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.....................................................................
5
1
INDICATIONS
..............................................................................................................
5
1.1 Pediatrics
.......................................................................................................................
6
1.2 Geriatrics
.......................................................................................................................
6
2
CONTRAINDICATIONS
.................................................................................................
6
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
............................................................ 7
4
DOSAGE AND ADMINISTRATION
................